JB Chemicals & Pharmaceuticals Limited
2,557words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
ironment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company
60%
istent track record across multiple businesses 5 Brands among top 300 brands, contributing over 60% of domestic formulations revenues 40+ Regulated/semi-regulated markets of presence through dir
24%
Top 5 Global manufacturer of medicated/herbal lozenges representing a substantial opportunity 24% Growth in chronic therapies* in the domestic formulations business 2500# Strong India field fo
22%
cused segmentation 7 Multi-dosage formulation plants with key global approvals/ compliances **22% ROCE with consistent cash flow generation generating good returns * CAGR over FY20-FY22 (IQVIA
18.6%
4 Corporate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) *Op EBITDA Margin (%) 18.6% 21.3% 1,643 1,775 15.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19
21.3%
porate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) *Op EBITDA Margin (%) 18.6% 21.3% 1,643 1,775 15.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20
15.4%
ancial Overview Revenue (INR cr) PAT (INR cr) *Op EBITDA Margin (%) 18.6% 21.3% 1,643 1,775 15.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20 FY21 FY22 15% 10%
27.4%
w Revenue (INR cr) PAT (INR cr) *Op EBITDA Margin (%) 18.6% 21.3% 1,643 1,775 15.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20 FY21 FY22 15% 10% FY18 24% 1
25.0%
nue (INR cr) PAT (INR cr) *Op EBITDA Margin (%) 18.6% 21.3% 1,643 1,775 15.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20 FY21 FY22 15% 10% FY18 24% 13% FY1
15%
5 15.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20 FY21 FY22 15% 10% FY18 24% 13% FY19 42% 25% 29% 19% 22% 18% FY20 FY21 FY22 ROE (%) ROCE (%) Incr
10%
.4% 1,413 27.4% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20 FY21 FY22 15% 10% FY18 24% 13% FY19 42% 25% 29% 19% 22% 18% FY20 FY21 FY22 ROE (%) ROCE (%) Increasin
13%
% 25.0% 2,043 2,424 139 194 272 449 386 FY18 FY19 FY20 FY21 FY22 15% 10% FY18 24% 13% FY19 42% 25% 29% 19% 22% 18% FY20 FY21 FY22 ROE (%) ROCE (%) Increasing Share of the D
Advertisement